



Market Announcement

21 January 2021

Cyclopharm Limited (ASX: CYC) – Trading Halt

Description

The securities of Cyclopharm Limited ('CYC') will be placed in trading halt at the request of CYC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 25 January 2021 or when the announcement is released to the market.

Issued by

Corey Lian

Graduate, Listings Compliance (Sydney)



21 January 2021

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclo**medica**
tech**ne**gas
ultra**lute**

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

By email: tradinghaltssydney@asx.com.au

Cyclopharm Limited (ASX: CYC) – Trading Halt Request

Pursuant to ASX Listing Rule 17.1, Cyclopharm Limited ACN 116 931 250 (Company) requests a trading halt of the Company's securities pending the release of an announcement relating to the completion of a capital raising. The capital raising will involve a placement of new shares to institutional and sophisticated investors.

The Company requests that the trading halt be effective immediately and remain in place until the earlier of the commencement of normal trading on Monday, 25 January 2021 or the release of an announcement by the Company in relation to the capital raising.

The Company is not aware of any reason why the trading halt should not be granted. For any questions, please contact the undersigned on +61 2 9541 0411.

This ASX announcement was approved and authorized for release by James McBrayer, Managing Director, CEO and Company Secretary

Yours faithfully

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

ENDS

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas™ used in functional lung ventilation imaging.

Technegas™

The Technegas™ technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas™, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.